Aldosterone Antagonist
PreclinicalSmall molecule
Aldosterone Antagonist is one of 35 small molecule programs targeting Hyperaldosteronism. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
157 competitors in Hypertension
#DrugCompanyPhaseTrials
1Baxfendy
AstraZenecaPhase 3
Foundayo
Eli LillyPhase 3
Nitrostat
VViatris Specialty LLC
Phase 3
Alka-Seltzer
AAbbott
Phase 3
SGLT2
PProf. Dr. med. Ingo Eitel
Phase 3
HCP1803-3
Hanmi Pharmaceutical Company LimitedPhase 3
Avastin
RochePreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aldosterone Antagonist. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IImperial College London